Effect of Montmorillonite powder on intestinal mucosal barrier in children with abdominal Henoch–Schonlein purpura: A randomized controlled study

    loading  Checking for direct PDF access through Ovid

Abstract

Background:

Our previous studies found that intestinal barrier function has been changed in children with abdominal Henoch–Schonlein purpura (HSP). Montmorillonite has been shown to be protective for digestive tract mucosa.

Objective:

The present study aimed to investigate whether Montmorillonite powder could improve the intestinal mucosal barrier function in children with abdominal HSP.

Methods:

Using a randomized controlled study design, we compared plasma levels of diamine oxidase (DAO), D-lactate, and endotoxin in children with abdominal HSP before and after Montmorillonite powder treatment.

Results:

Among 28 patients in experimental group and 30 in control group, there was no significant difference in age, sex, height, weight, and course of disease between 2 groups (P > .05). Before treatment, there was no statistical difference in DAO, D-lactic acid, and endotoxin between experimental group and the control group (P > .05). However, significant differences were detected for DAO and D-lactate after treatment in comparison to before treatment in the Montmorillonite experimental group (P < .05). Such differences were not found in the control group (P > .05).

Conclusion:

Montmorillonite powder is effective in the treatment of HSP via maintaining intestinal mucosal barrier function.

Related Topics

    loading  Loading Related Articles